Gyre Therapeutics Receivables

Gyre Therapeutics (GYRE) currently reports a receivables of $23M as of March 2026. That compares with $20M in the prior-year period — up 13.0% year over year. Use the charts on this page to explore Gyre Therapeutics's receivables history and peer comparisons.

Gyre Therapeutics's receivables increased from $20M to $23M — a 13.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Gyre Therapeutics reported $23M in receivables as of March 2026. That compares with $20M in the prior-year period — up 13.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $23M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Gyre Therapeutics, and consider following GYRE for alerts when major investors trade the stock.

Gyre Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $23M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GYRE with unrelated industries.